S
15.25
-0.23 (-1.49%)
| Penutupan Terdahulu | 15.48 |
| Buka | 15.50 |
| Jumlah Dagangan | 2,596,734 |
| Purata Dagangan (3B) | 5,476,367 |
| Modal Pasaran | 11,836,480,512 |
| Harga / Buku (P/B) | 21.68 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.340 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.87% |
| Nisbah Semasa (MRQ) | 10.63 |
| Aliran Tunai Operasi (OCF TTM) | -173.14 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -104.80 M |
| Pulangan Atas Aset (ROA TTM) | -52.50% |
| Pulangan Atas Ekuiti (ROE TTM) | -123.93% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Summit Therapeutics Inc. | Bercampur | Menurun |
AISkor Stockmoo
1.8
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.83 |
|
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 84.32% |
| % Dimiliki oleh Institusi | 13.52% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Apeiron Capital Ltd | 31 Mar 2026 | 1,309,141 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 31 May 2026 | CNBC | A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |